First Capital Ventures
VC Fund
Greenwood Village, United States
First Capital Ventures is a VC fund in Greenwood Village focused on Medical and Genetics. First Capital Ventures invests in innovative technologies that disrupt an industry or emerging technology companies in new industries that disrupt the marketplace. We focus on entry strategy and exit strategy at the same time with a targeted 24-36 month investment horizon.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 67%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries First Capital Ventures invests in
Stages First Capital Ventures invests in
Countries First Capital Ventures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Brent Johnson
|
|||
Justin Davis
|
|||
Scott Morris
|
|||
|
David Gandini
|
|||
Erin Turoff
|
|||
| See all 7 contacts → | |||
Investment Focus
Industry
- Medical 2 (67%)
- Genetics 1 (33%)
- Security 1 (33%)
- Software 1 (33%)
- Wellness 1 (33%)
Stage
- Series A 2 (67%)
- Venture - Series Unknown 1 (33%)
Country
- United States 2 (67%)
- United Kingdom 1 (33%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Brent Johnson
Managing Director & General Counsel
|
Managing Director & General Counsel | Total investments: 0 | Find email | |
|
Justin Davis
SVP, Investor Relations
|
SVP, Investor Relations | Total investments: 0 | Find email | |
|
Scott Morris
CFO
|
CFO | Total investments: 0 | Find email | |
|
David Gandini
Managing Partner
|
Managing Partner | Total investments: 0 | Find email | |
|
Erin Turoff
COO & Managing Director
|
COO & Managing Director | Total investments: 0 | Find email | |
| See all 7 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Syncell
|
Syncell is a life science technology company building products for next-generation spatial biology. Its pioneering Microscoop™ technology enables microscopy-guided nanoscale protein "scooping", making unbiased subcellular spatial proteomics discovery feasible for the first time. This technology can be applied to a broad range ofbiological problems to help understand molecular mechanisms, identify novel disease biomarkers, and reveal novel druggable targets. | $25.7M / Series A / Jun 30, 2025 | |
B-Secur
|
B-Secur are on a mission to revolutionise the way people experience technology in the connected world using their unique heartbeat. We’ve invested over 15 years of deep, scientific research in ECG to become a world leader in the development and integration of ECG technology, partnering with some of the world's leading technology companies.We’ve harnessed the power of ECG to create HeartKey®, offering advanced physiological monitoring with intrinsic data protection.We have developed a suite of powerful ECG algorithms and analytics for user identification, wellness, and health, ready for integration into leading devices and systems. B-Secur also have a combined 50+ years of in-house hardware and material science, which our partners can use to significantly reduce development costs on hardware and ECG electrode design. B-Secur and HeartKey® bring you our world class expertise in ECG combined with powerful, flexible integration and configuration possibilities to create your optimal product, with a competitive edge. | $11.9M / Venture - Series Unknown / Nov 04, 2021 | |
Kromatid
|
KromaTiD focuses on advancing the knowledge of genetic abnormalities and diseases by developing molecular cytogenetics assays and reagents.It's molecular cytogenetic and GeneTracker assays discover, detect, and diagnose the range of disease-causing mutations - including inversions and translocations - in a single test. Based on DirectionalGenomic Hybridization (dGH), KromaTiD's assays generate the sequence, location, and orientation data from single cells, making them ideal for mixed cell population studiesCo-founders Andrew Ray, Joel Bedford, Michael Cornforth, and Susan M. Bailey headquartered the company in Fort Collins, Colorado in 2007. | Series A / Aug 13, 2019 |
Co-Investors
Kernel Capital
2 deals together
Co-FundNI
1 deal together
Himalaya Capital Ventures
1 deal together
Hua Nan Financial Holdings
1 deal together
ITIC: Industrial Technology Investment Corporation
1 deal together
Isaiah Capital
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does First Capital Ventures invest in?
First Capital Ventures invests primarily in Medical, Genetics and Security startups, most often at Series A and Venture - Series Unknown stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact First Capital Ventures?
Public channels for First Capital Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at First Capital Ventures?
The team at First Capital Ventures includes Brent Johnson (Managing Director & General Counsel), Justin Davis (SVP, Investor Relations) and Scott Morris (CFO), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
